IL6 and COVID-19: Ten patients (19.2%) reported having methotrexate monotherapy before COVID‐19 onset, while antimalarials monotherapy and IL‐6 inhibitors monotherapy were reported in 5 patients (9.6%) and 4 patients (7.7%), respectively, Table S1.